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Central hypogonadotropic hypogonadism (CHH) is an emerging pathological condition frequently associated with overweight,
metabolic syndrome, diabetes, and midline defects. The genetic mechanisms involve mutations in at least twenty-four genes
regulating GnRH neuronal migration, secretion, and activity. So far, the mechanisms underlying CHH, both in prepubertal and in
adulthood onset forms, remain unknown in most of the cases. Indeed, all detected gene variants may explain a small proportion
of the affected patients (43%), indicating that other genes or epigenetic mechanisms are involved in the onset of CHH. The aim of
this review is to summarize the current knowledge on genetic background of CHH, organizing the large amount of data present in
the literature in a clear and concise manner, to produce a useful guide available for researchers and clinicians.
1. Introduction
The physiological function of the human hypothalamic-
pituitary-gonadal (HPG) axis is based on the pulsatile release
of hypothalamic gonadotropin-releasing hormone (GnRH)
[1]. In vertebrates, the decapeptide GnRH regulates the secre-
tion of luteinizing hormone (LH) and follicle-stimulating
hormone (FSH) from anterior pituitary gonadotropes, gov-
erning the onset of puberty, gametogenesis, and in females,
estrous/menstrual cycling [2].
During postnatal life, GnRH-secreting neurons are inte-
gral members of the HPG axis. During embryonic devel-
opment, these cells originate from an extracerebral region,
namely, the nasal placode, and migrate to the hypothalamus,
closed to olfactory-vomeronasal nerves (VNNs) [2, 3]. The
correct development and coordinated function of the GnRH-
secreting neurons and the gonadotropes are essential for
the correct activation of the gonads during foetal life and
the neonatal period (the so-called “minipuberty”). After a
dormant phase during infancy and childhood,HPGactivity is
resumed at the time of the puberty and throughout the adult
reproductive age [1].
In human males, after birth, the HPG axis is active until
approximately 6 months of life, with gonadotropin and sex
steroids concentrations peaking between 4 and 12 weeks of
life. After this period, GnRH pulsatility declines and the
HPG axis becomes quiescent throughout childhood. Onset
of puberty is characterized by pulsatile GnRH release from
the hypothalamus that stimulates pituitary LH secretion,
which, in turn, drives testosterone production by testicular
Leydig cells [4, 5]. GnRH also increases FSH secretion,
which promotes maturation of the seminiferous tubules and
spermatogonia [5]. Adrenarche, at about 6-7 years of age,
starts when the adrenal androgen, DHEA, DHEAS, and
androstenedione concentrations, produced by adrenal zona
reticularis, begin to increase in the circulation [5, 6]. Adrenar-
che continues up to approximately 14 years of age in both
sexes [4, 7]. Pubarche frequently starts simultaneously with
testicular development, while axillary hair growth occurs at
about the time of peak height velocity (about 14 years of age)
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[8]. Delayed puberty is usually defined as the absence of signs
of puberty by age 14 in boys [7].
In human females, during childhood the ovarian cycle,
controlled by HPG axis, is quiescent [9]. Adrenarche (6–8
years of age), clinically evident with pubic and axillary hair
growth [7, 9], is followed by gonadarche and during this
period the nocturnal LHpulse occurs, leading to ovarian pro-
duction of testosterone and progesterone. Gonadal steroids
facilitate the pubertal growth spurt and breast development
(thelarche), that generally begins about age 8-9 years, leading
to menarche [7, 9]. A growth spurt occurs at 12 years
of age, and subsequently, the first menstrual cycle occurs
(menarche) [7]. Menarche, induced by follicle growth and
estradiol production, occurs with the initial shedding of
the endometrium with subsequent bleeding. Female puberty
ends when women ovulate and repeated ovulatory cycles
ensure reproductive competence [9, 10].
The complex disease called central hypogonadotropic
hypogonadism (CHH) is able to seriously compromise the
physiologic function of the HPG axis in both sexes. CHH is
characterized by delayed or absent sexual development and
infertility associated with inappropriately low gonadotropins
(LH and FSH) and sex steroids (testosterone or estradiol)
levels in the absence of anatomical or functional abnormal-
ities of the HPG axis [11–13]. In patients with normal levels
of circulating gonadotropins, LH and FSH are secreted in a
nonpulsatile manner and are ineffective at the target level [1].
CHH is a rare disease with an incidence of 1 : 8000 females
and 1 : 4000 males [1]. The disease associated with a normal
sense of smell, occurring in 40–45% of CHH patients [13], is
called normosmic Idiopathic Central hypogonadism (nICH)
or normosmic hypogonadotropic hypogonadism (nHH).
When a defective sense of smell, hyposmia or anosmia, is
associated with hypogonadotropic hypogonadism, in 60%
of patients [13], the disease is called Kallmann syndrome
(KS), explained by the common embryonic origins and
developmental pathways of GnRH and olfactory neurons
[1, 11, 12, 14]. CHH is either congenital or acquired, and it
can be isolated or combined with other pituitary hormone
defects [1]. Male patients affected by CHH frequently present
a defective androgenisation and growth at a peripubertal age,
butmicropenis and cryptorchidismmay already be evident in
the neonatal period, indicating a defective activation of HPG
during prenatal development. Female patients generally show
primary amenorrhea and growth retardation.Midline and/or
kidney defects may be present and can be linked to specific
modes of inheritance [1, 15].
In the past two decades, hypogonadotropic hypogo-
nadism was considered an irreversible disease, to treat with
a long-life hormonal exposure. By contrast, it is well known
that a small proportions of male patients, up to 10%, after
exposure to androgens therapy, may undergo reversal of
hypogonadism [16]. Patients affected by KS or normosmic
HH with mutations in fibroblast growth factor receptor 1
(FGFR1), KAL1, GNRHR, and CHD7 genes or with still
unknown genetic defectswere reported to present a reversible
phenotype, after therapywithdrawal [17–21]. In these patients
a spontaneous recovery of LH pulsatile secretion occurred
together with normalization of the testosterone level after
therapy suspension [20]. Although the precise mechanism
of reversal of hypogonadotropic hypogonadism is unclear,
plasticity of the GnRH-producing neurons in adulthood
could be involved [20]. The ability of the nervous system to
adapt in response to environment is a striking feature of the
vertebrate brain. Although, neurogenesis in humans occurs
primarily during embryonic and early postnatal stages,
multipotential progenitor cells in the subcortical whitematter
of the adult human brain have been identified as having
the potential to replace neuronal lineages [22]. Furthermore,
the neurons in the olfactory epithelium and in the dentate
gyrus of the hippocampus are generated throughout life [23–
25] and their generation appears to be modulated by sex
steroids [26]. A current hypothesis to explain reversal of
hypogonadotropic hypogonadism suggests the action of sex
steroids in enhancing the plasticity of the neuronal network
producing GnRH in the adult human brain [20].
2. Diagnosis and Treatment of CHH
The diagnosis may be suspected before puberty when
boys present micropenis and/or unilateral or bilateral cryp-
torchidism and in the presence of other associated congenital
abnormalities, such as midline defects (cleft palate, short
metacarpals, hearing loss, bimanual synkinesia, etc.) [1, 27].
In contrast, newborn girls have no obvious abnormal charac-
teristics suggesting a congenital CHH diagnosis. Adult-onset
CHH is characterized by secondary amenorrhea, decreased
libido, infertility, and osteoporosis, in women and symptoms
of decreased libido, lack of morning erection, erectile dys-
function, inability to perform vigorous activity, depression,
fatigue and infertility, in men [28].
The measurement of morning total testosterone is
strongly recommended as the initial diagnosis test [29],
especially assessing free or bioavailable testosterone levels
[30]. Although widely used in the past, the practical value
of the GnRH test has been questioned because this test does
not provide extra diagnostic information compared to base-
line gonadotropin levels [28]. The pituitary function can
be first evaluated by basal hormonal levels (measured by
ultrasensitive assays).Thyroid function should be assessed by
TSH combined with free T4. IGF-I can be used to evaluate
the somatotropic axis, whereas secondary adrenal deficiency
can be assessed by measuring a morning cortisol and ACTH.
Anosmia can be diagnosed by questioning the patient and by
olfactometry as the University of Pennsylvania smell iden-
tification test, useful to determine a normal or partially
defective olfaction [28].
Magnetic resonance imaging (MRI) of the hypothalamus-
pituitary region is very useful in the management of CHH
because MRI can demonstrate a malformation or tumors.
Renal ultrasound examination is usually recommended to
patients with syndromic CHH, such as Kallmann syndrome.
The genetic study is usually the final step in the CHH inves-
tigation and a complete clinical characterization could be
very useful in the selection of the gene/s to be screened [28].
International Journal of Endocrinology 3
Table 1: Human genes involved in CHH.
Genes Location Gene ID Structure(coding exons) Inheritance OMIM Phenotype
KAL1 Xp22.3 3730 14 XR 308700 KS
FGFR1 (KAL2) 8p12 2260 17 AD 147950 KS
FGF8 (KAL6) 10q24 2253 6 AD 612702 nHH
PROK2 (KAL4) 3p13 60675 4 AR 610628 KS
PROKR2 (KAL3) 20p12.3 128674 2 AD, AR 147950 KS, nHH
CHD7 (KAL5) 8q12.2 55636 37 AD 612370 CHARGE, KS, nHH
NELF 9q34.3 26012 14 Digenic 614838 KS
GNRH1 8p21-p11.2 2796 3 AR 614841 nHH
GNRHR 4q21.2 2798 3 AR 146110 nHH
LEP 7q31.3 3952 2 AR 614962 nHH
LEPR 1p31 3953 18 AR 614963 nHH
TAC3 12q13-q21 6866 5 AR 614839 nHH
TACR3 4q25 6870 5 AR 614840 nHH
KISS1 1q32 3814 2 AR 614842 nHH
KISS1R (GPR54) 19p13.3 84634 5 AR 614837 nHH
PCSK1 5q15-q21 5122 14 AR 162150 nHH
WDR11 10q26 55717 29 AD 614858 KS, nHH
HS6ST1 2q21 9394 2 Unclear 614880 KS, nHH
SEMA3A 7p12.1 10371 17 AD, di/oligogenic 614897 KS
SEMA7A 15q22.3-q23 8482 14 Di/oligogenic 607961 nHH, KS
LHB 19q13.32 3972 3 AR 152780 nHH
FSHB 11p13 2488 2 AR 136530 nHH
NDN 15q11.2-q12 4692 1 Unknown 602117 KS, Prader-Willi




Gene ID: identification number assigned to a specific gene in NCBI database; OMIM: online catalogue of human genes and genetic disorders, numbers refer to
the first search result including the gene name and the term “hypogonadism;” KS: Kallmann syndrome; nHH: normosmic hypogonadotropic hypogonadism;
XR: X-linked recessive; AR: autosomic recessive; AD: autosomic dominant; OFC: syndromic orofacial cleft; CAA: congenital aural atresia.
The aims of therapy in hypogonadal adolescents or young
adults are the induction and maintenance of normal puberty
and induction of fertility.
Testosterone therapy is recommended in adult men with
symptomatic androgen deficiency to improve sexual function
and to increase muscle mass and strength. Testosterone is the
primary useful treatment to induce and maintain secondary
sexual characteristics and sexual function in affected men,
but it does not restore fertility [28]. Several testosterone
formulations are currently available such as intramuscular
injections of long-acting testosterone esters, gel formulations,
or testosterone patches applied nightly [29]. When fertility is
desired, gonadotropin therapy is necessary to induce sper-
matogenesis in affected males. The common gonadotropin
therapy combines human chorionic gonadotropin (hCG) and
follicle stimulating hormone (FSH) [31, 32].
3. Genetic Basis of CHH
A small percentage of patients (approximately 4%) shows a
chromosomal rearrangement as cause of CHH or KS [7, 33],
but the majority of hypogonadic patients harbour a mutation
in a single or more genes.
Isolated GnRH deficiency, caused by defects in the secre-
tion or action of hypothalamic GnRH, is one of the rare
genetic diseases originally thought to be strictly monogenic
but the numerous studies about this disorder led to the
discovery of several new loci [34] (Table 1), with key roles
for the developmental and neuroendocrine control of human
reproduction [1, 12, 14]. So far, twenty-four genes have been
identified (Table 1).
The proteins, encoded by the genes involved so far in this
pathology, have been grouped, according to their function,
in three functional categories: development and migration of
GnRH neurons, regulation of GnRH secretion, and GnRH
and gonadotropins action [1, 11, 12, 35] (Figure 1). However,
the function of some genes, recently identified, is not fully
clear.
Althoughmultiplemutations have been identified in each
gene, in the majority of affected patients (approximately
60%), no mutations can be found, signifying that yet more
disease loci remain to be discovered [14].
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Figure 1: Scheme of all human CHH-related genes involved and supposed to be involved at different steps in the hypothalamic-pituitary-
gonadal axis development and functioning. All three main steps leading to the HPG axis formation are reported in this picture. Upper side:
list of the genes, implicated in the development of GnRH neurons and their migration towards the olfactory bulb, during the embryonic
development. Middle part: genes involved in the regulation of GnRH secretion. Lower side: genes implicated in the direct action of GnRH
on pituitary and in its indirect action on gonads.
3.1. KAL1. The KAL1 gene, located on the short arm of
chromosome X (Xp22.3), contains 14 exons and encodes the
extracellular matrix glycoprotein anosmin-1, which appears
to be involved in the migration of GnRH and olfactory
neurons during embryologic development [36] (Figure 1).
Hypogonadism in KS, due to GnRH deficiency, probably
results from a failure of the embryonic neuronal migration,
and the defective sense of smell is related to the hypoplasia
or aplasia of the olfactory bulbs and tracts [37]. Anosmin
1 is a secreted protein containing a cysteine-rich region,
a highly conserved four disulfide core whey acid protein
(WAP) domain, four fibronectin type III (FNIII) repeats
(including FNIII-1, FNIII-2, FNIII-3, and FNIII-4 repeat),
and a C-terminal histidine-rich region [36].
Mutations in the KAL1 gene were first described in males
with X-linked recessive KS [38]. So far, in the literature, over
60 different mutations were described including deletions,
missense, frameshift [39], and gross rearrangements [37, 40].
About half of the mutations fall inWAP domain and in FNIII
repeats suggesting their important role in the correct function
of anosmin-1 [41]. All KAL1mutations account for 33 to 70%
of familial cases of KS and 3.1 to 27.8% of apparently sporadic
forms of known KS [36, 37].
3.2. FGFR1 (KAL2) and FGF8 (KAL6). FGFR1, encoding
fibroblast growth factor receptor-1, is a member of the recep-
tor tyrosine kinase superfamily. FGF signalling controls cell
proliferation, migration, differentiation, survival and plays
essential roles in various processes of embryonic develop-
ment. In the presence of heparin sulphate proteoglycans
(HSPG), FGF8 (fibroblast growth factor-8) binds with high
affinity to FGFR1 and induces receptor dimerisation, and its
activation [42, 43]. The FGFR1 is involved in gastrulation,
organ specification, patterning of many tissues, including the
brain, as well as the development of the olfactory system [43]
(Figure 1).
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Both FGFR1 and FGF8, mapping on 8p12 and 10q24,
respectively, can cause an autosomal dominant form of KS.
The majority of mutations in FGFR1 or FGF8 are missense
mutations. Notably, about 30% of the FGFR1 variants found
are de novomutations [39]. In KS patients, skeletal anomalies
such as syndactyly, polydactyly, or camptodactyly were exclu-
sively seen in presence of FGFR1/FGF8mutations [44].
3.3. PROK2 (KAL4) and PROKR2 (KAL3). The PROK2 gene,
on chromosome 3p13, encodes the protein prokinetecin 2,
an 81-amino acid peptide that signals via the G protein-
coupled product of the PROKR2 gene, on chromosome
20p12.3 [45]. The amino-terminal domain of prokineticin 2
contains a sequence of six amino acid residues (AVITGA),
which is conserved in all mammalian and nonmammalian
orthologs. Prokineticins can bind to two different G protein-
coupled receptors, PROKR1 and PROKR2, sharing about 85%
sequence identity. They have a central core, formed by seven
transmembrane domains (TM1–TM7), connected by intra-
cellular and extracellular loops. PROKR1 is mainly expressed
in peripheral tissues, including endocrine glands whereas
PROKR2 shows relatively localized distribution in the central
nervous system, in particular in the subventricular zone
(SVZ) and in the olfactory bulbs [46]. It has been shown that
this ligand-receptor system is essential for normal olfactory
bulb and reproductive system development in mice and in
patients with CHH. Homozygous mutant Prokr2 knockout
mice show abnormal development of the olfactory bulb and
severe atrophy of the reproductive system, but no significant
abnormalities were observed in the heterozygous mice [37].
The knockout models for either ligand (Prok2) or receptor
(Prokr2), revealed a role in olfactory bulb morphogenesis
and sexual maturation, indicating PROK2 and PROKR2 as
strong candidate genes for human GnRH deficiency [47].
Mutations described within the PROK2/PROKR2 system
account for less than 10% of subjects with KS and normosmic
HH [37]. Nonreproductive, non-olfactory clinical anomalies
associated with Kallmann syndrome seem to be restricted to
patients with monoallelic mutations [45].
3.4. CHD7 (KAL5). The chromodomain helicase DNA bind-
ing protein 7 (CHD7), on chromosome 8, encodes a
chromatin-remodelling factor belonging to a family of nine
CHD proteins and having in common the ability to utilize
ATP hydrolysis to alter nucleosome structure [45, 48]. The
large 2997 amino acid CHD7 protein contains two important
chromodomains at its N terminus [48]. Chromodomains
have been thought to mediate chromatin interactions and
were found to interact with DNA, RNA, and histone targets
[48].
Heterozygous mutations in CHD7 are found in more
than 60% of the patients with typical CHARGE syndrome,
a multisystem autosomal-dominant or sporadic disorder
including coloboma, heart anomalies, choanal atresia, retar-
dation, genital, and ear anomalies [49]. In the literature 3 to
5% of patients with CHH or KS were found to have a CHD7
mutation [50].
Previous studies on CHD7 suggested that the analysis
of this gene should be performed in KS patients having
at least two CHARGE syndrome features. Following this
guideline, Bergman and colleagues [51] performed the CHD7
analysis in a cohort of 36 Dutch KS patients (previously
excluded to carry mutations in FGFR1, PROK2, PROKR2,
and FGF8), identifying 3 heterozygous CHD7 mutations
in patients having same features of CHARGE syndrome.
Conversely, in the study of Kim et al. [48], mutations in
this gene were found also in KS patients not carrying any
CHARGE features. Thus, considering these findings, new
studies on CHD7 and hypogonadic patients are needed.
3.5. NELF. NMDA receptor synaptonuclear signalling and
neuronal migration factor, also known as Nasal Embryonic
LHRH Factor (NELF), maps on chromosome 9. The mode
of inheritance of CHH is likely to be autosomal recessive
because biallelic mutations, reducing protein expression in
vitro, have been described in the literature in only one KS
patient without mutations in other genes, whereas heterozy-
gousNELFmutationswere only found in affected normosmic
HH/KSpatientswith heterozygousmutations in another gene
[52].
NELF is a good candidate gene for a role in GnRHneuron
migration, mammalian puberty, and the pathophysiology
of KS. Over ten years ago, the mouse NELF was cloned
from a differential cDNA library screen of migratory versus
nonmigratory GnRH neurons [53]. Its expression was found
to be aligned along the plasma membrane of olfactory and
GnRH neurons before they enter the hypothalamus and is
downregulated when GnRH neurons reach the forebrain.
Moreover, reducing NELF protein expression, GnRH neu-
rons are reduced in number and GnRH nerve fiber decrease
in complexity and length [53]. Two studies implicated NELF
in KS [54, 55]. Subsequently, that data were confirmed
by Xu et al. [56], who correlated human NELF mutations
with monogenic normosmic HH/KS. Xu and colleagues [56]
demonstrated that NELF protein was more expressed in
migratory versus postmigratory GnRH neuronal cells and
NELF knockdown dramatically impairs GnRH neuronal cell
migration in vitro. A functional nuclear localization signal
and two putative zinc fingers identify NELF as a nuclear
protein, possibly a transcription factor [56, 57].
3.6. GNRH1 and GNRHR. GnRH plays a key role in the con-
trol of reproductive function (Figure 1). It is synthesized in a
small number of hypothalamic neurons and released in a pul-
satile manner into the hypophyseal portal circulation reach-
ing the anterior pituitary, where, binding to specific receptors
(GnRHRs), regulates gonadal steroidogenesis in both sexes,
stimulating synthesis and release of the two gonadotropins
(LH and FSH) [58] (Figure 1). Human GNRH1, on chromo-
some 8, composed by four exons separated by three introns,
encodes a 92 amino acids preproprotein (pre-pro-GnRH),
consisting of a signal sequence (23 amino acids) sequentially
followed by two serine residues, the GnRH decapeptide, a
GKR sequence, and a 56-amino acid peptide called GAP
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(GnRH-associated peptide) [58, 59].Themature decapeptide
sequence is conserved among most mammals [60].
In two studies, mice, carrying a deletion ofGnrh1, showed
a complete absence of GnRH synthesis [61, 62]. Moreover,
these mice were sexually immature, infertile, and exhibited
low sex steroid and gonadotropin levels [61, 62]. These
findings in the mouse suggested that mutations in human
GNRH1 could cause CHH. Variants of the human GNRH1
gene are very rare. Naturally occurring mutations in human
GNRH2 were not described so far. The p.R31C mutation
is the sole missense mutation affecting the mature GnRH
decapeptide sequence, encoded by GNRH1, described so far
[60]. This mutation, in which arginine is substituted by
cysteine in position 8 of the mature decapeptide, represents
a hot spot [52, 59].
The other variants described were detected in the extra
decapeptide positions such as p.R73X, p.T58S, and p.V18M
[59]. All these variants were described in heterozygous state
but curiously, Chan et al. [59] reported also a homozygous
mutation, p.G29GfsX12, in amale patientwith severe congen-
ital CHH. This single base-pair deletion causes a frameshift
that was predicted to disrupt the GnRH decapeptide [59].
The GnRH receptor (GNRHR) gene, differently from that
encoding its ligand, accounts for many inactivating muta-
tions, resulting in impairment of GnRH action [63]. GNRHR
is a 328-amino acid protein encoded by a gene located
on chromosome 4q21.2. Its activation results in increased
activity of phospholipase C and mobilisation of intracel-
lular calcium [1]. GNRHR contains seven transmembrane
domains and an extracellular 35-amino acid amino-terminal
domain with two putative glycosylation sites. Interestingly,
this receptor does not have a carboxy-terminal cytoplasmic
tail, thus, it internalizes relatively slowly and it does not
rapidly desensitize [58]. Inactivating mutations of GNRHR
were the first to be recognized as monogenic causes of CHH
condition [64]. Null GNRHR mice models display a similar
phenotype to human CHH [1]. Over 22 human GNRHR
inactivating mutations, with no hotspot, were described [63]
and these different genotypes result in a wide phenotypic
spectrum, ranging from fertile eunuch syndrome and par-
tial hypogonadotropic hypogonadism to the most complete
form of GnRH resistance, characterized by cryptorchidism,
micropenis, undetectable gonadotropins and the absence
of pubertal development [1]. Although many defects in a
large number of different genes were associated to CHH,
GNRHR is still the most commonly affected gene in this
pathogenic condition [64]. Since the vast majority of patients
harbouring GNRHR mutations are resistant to GnRH, the
effective fertility treatment is achieved with gonadotropins
[63].
3.7. LEP and LEPR. Adipose tissue, through expression and
secretion of leptin, plays a dynamic role inwhole-body energy
homeostasis by acting as an endocrine organ [65]. Twenty
years ago, a mouse model, named “ob/ob,” was discovered to
have an inactivating mutation of the Ob gene in both alleles,
causing a complete deficiency of the ob gene product, to date
known as Leptin (Lep) [66]. Interestingly, overweight in these
mice, with metabolic, endocrine, and immune disturbances,
regressed under exogenous leptin administration [67].
Leptin, encoded by human LEP gene, on chromosome
7q31.3, is a 167-amino acid peptide with a four-helix bundle
motif similar to that of a cytokine. It is produced, in a
pulsatilemanner, following a circadian rhythm, principally in
adipose tissue but also in other different districts such as pla-
centa, ovaries, and mammary epithelium [67]. Leptin and its
receptor (LEPR) are present also in human spermatozoa and
seminiferous tubules [68]. A few studies described human
families with congenital leptin deficiency with early onset of
obesity, hyperphagia, hypogonadotropic hypogonadism, and
delayed puberty. Interestingly, inactivating mutation of the
leptin receptor gene, encoded by human LEPR on chromo-
some 1p31, caused less severe clinical features, indicating that
probably, in case of receptor dysfunction, leptin is able to
interact with other molecules to exert its action [67, 68]. On
the basis of recent findings, human Leptin is supposed to
be implicated in the secretion of GnRH through stimulation
of several hypothalamic neurons, secreting neuropeptide
Y, proopiomelanocortin, and kisspeptin 1 [67, 68]. In the
presence of leptin resistance, due to obesity, leptin is supposed
to be unable to stimulate GnRH secretion, with consequent
low levels of FSH and LH and hypogonadism [67, 68].
3.8. TAC3 and TACR3. Mammalian tachykinins comprise
a protein family including substance P (SP), neurokinin
A (NKA), neurokinin B (NKB), and hemokinin-1 (HK-1).
Human tachykinins, characterized by a common C-terminal
amino-acid sequence (Phe-X-Gly-Leu-Met-NH2) [69], are
encoded by three different genes. TAC1, TAC3, and TAC4
[70]. The TAC3 gene encodes the NKB. Studies suggest that
these peptides have a role as mediators of nonadrenergic
and noncholinergic excitatory neurotransmission and recent
data show that tachykinins are present in human sperma-
tozoa and participate in the regulation of sperm motility
[69]. Tachykinins (SP, NKA, and NKB) interact with three
receptors, NK1R, NK2R, and NK3R [69, 71, 72]. The specific
interactions of the three tachykinins with each of these
receptors and their affinity vary as follows: SP >NKA >NKB
for NK1R; NKA >NKB > SP for NK2R; NKB >NKA > SP for
NK3R [71].
The particular ligand/receptor system NKB/NK3R,
(encoded by TAC3/TACR3), previously investigated only
for preeclampsia, alcohol, and cocaine dependence [73–75],
gained an increasingly important role in human reproductive
axis and in CHH onset in the last seven years. So far, over
40 CHH patients with TAC3 and TACR3 mutations have
been reported, with a worldwide distribution [45, 76–79].
These patients are characterized by absence of pubertal
development with low circulating levels of serum LH, low
gonadal steroids and high prevalence of microphallus,
indicating that NKB/NK3R signalling is essential for the
normal activation of the reproductive axis late in gestation
[45, 76–79]. Recent evidences suggest that NKB is able to
modulate gonadotropin release through its action on Kiss1
neurons [71, 80], but many aspects of the physiology of the
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Table 2: Nucleotide variants identified so far in the two human
genes TAC3 and TACR3.
Gene Variants




















NKB/NK3R system in the context of reproduction remain to
be fully characterized.
The TAC3 gene maps on chromosome 12q13-q21 and
it is composed of 7 exons, 5 of which are translated to
form the preprotachykinin B peptide. This prepropeptide
undergoes enzymatic cleavages to formfirst proneurokinin B,
and then mature NKB. The amino acid sequence of the final
active peptide is encoded by exon 5 only [81]. So far, three
causative mutations, a splicing variant (c.209-1G>C) [12, 79],
a frame-shift variant (G20fsX39) [76] and a missense variant
(M90T) [78], were detected in CHH patients (Table 2). All
these mutations (Table 2) occurred in homozygous state,
suggesting an autosomic recessive inheritance.
The gene encoding the NKB receptor (TACR3), on chro-
mosome 4q25, is composed by five exons. The identified
mutations, either synonymous, or nonsynonymous or affect-
ing physiologic splicing, are widely distributed along the
gene, covering all main domains [12, 15, 76–78, 82] (Table 2).
3.9. KISS1 and KISS1R (GPR54). Kisspeptin-1, encoded by
KISS1 gene, on chromosome 1q32, was early identified in 1996
as a suppressor of metastasis in human malignant melanoma
[83]. The KISS1 gene, encodes for a 54-amino acid peptide,
also called kisspeptin 54, which corresponds to residues 68–
121 of the preproprotein.
Its receptor, KISS1R, also known as GPR54, is encoded
by a gene mapping on chromosome 19p13.3. In 2009, inacti-
vating mutations in homozygous state in KISS1R were found
in members of consanguineous families with a history of
normosmic HH, revealing the reproductive roles of KISS1R
and its ligand [11]. So far, mutations in the genes encoding
the kisspeptin 1 and TAC3, as well as mutations in their
receptors (KISS1R and TACR3, resp.), are associated with
GnRH deficiency and a failure to initiate and/or progress
through puberty [84]. Inactivating mutations in KISS1 and
KISS1R show an autosomal recessive pattern of transmission.
Only few patients with KISS1Rmutations have been reported
to date [85]. Thanks to experiments in mice, researchers
hypothesized that the system ligand/receptor TAC3/TACR3
is able to regulate the kisspeptin-1 release, which, through the
interaction with the receptor KiSS-1R, stimulates the GnRH
release and the normal reproductive function [80, 84].
3.10. PCSK1. Proprotein/neuroendocrine convertase defi-
ciency, caused by rare mutations in PCSK1 gene, has been
associated with obesity, severe malabsorptive diarrhea, and
certain endocrine abnormalities [86]. Neuroendocrine con-
vertases are enzymes processing large precursor peptides to
release bioactive fragments, as in the case of the proopi-
omelanocortin, which is processed by neuroendocrine con-
vertase 1 (NEC 1), encoded by PCSK1 gene, on chromosome
5q15-q21, in the corticotroph to produce adrenocorticotropic
hormone and lipotropin [11]. The first PCSK1 mutation, a
compound heterozygous mutation, was identified in 1997, in
a patient with obesity and hypogonadotropic hypogonadism
(Gly483Arg and a donor splice site mutation in intron 5,
causing skipping of exon 5 and the creation of a premature
stop codon) [87]. In other two patients with a similar
phenotype, a compound heterozygous mutation (Glu250X
and Ala213del) and a homozygous Ser307Leu substitution
were identified in PCSK1 [88, 89]. So far, PCSK1 is thought to
act on GnRH prohormone processing, even if the molecular
mechanisms are still unclear [11, 86].
3.11. WDR11. The WDR11 gene, on chromosome 10q26,
encodes for a 1224 amino acid protein, originally identified
as a potential tumor suppressor in human glioblastoma
cells [90]. The identification of human WDR11 mutations in
normosmic HH/KS, absent in controls, indicate that WDR11
plays an important role in human puberty. So far, five
missense mutations were identified (R395W, H690Q, F1150L,
A435T, and R448Q) [35, 91]. Four of these, R395W, H690Q,
F1150L, andA435T are completely conserved in all 11 available
mammalian orthologs, suggesting that these substitutions in
six independent, sporadic patients could be very deleterious.
All five described variants were in heterozygous state, sug-
gesting an autosomal-dominant inheritance. The absence of
truncating nonsense and frameshiftmutations could indicate
a more severe phenotype or an embryonic lethality [35, 91].
3.12. HS6ST1. Hs6st1 (Heparan sulphate 6-O-sulfotransfer-
ase 1), belonging to a class of molecules involved in neuronal
development, is highly expressed in the brain [92]. Recently,
the gene HS6ST1, mapping on chromosome 2q21, was found
to be mutated in seven patients with hypogonadism with
either normal olfaction (nHH) or variable degrees of olfac-
tory dysfunction (KS) [92]. All identified mutations affect
amino acid residues that are highly conserved in HS6ST1
but segregate as a complex trait in families, not following
Mendelian criteria (Table 1). The study of Tornberg et al.
[92] suggests that the identified HS6ST1 missense mutations
could not be sufficient to cause disease, indicating a prob-
able cooccurrence of other mutated genes. Considering the
importance of heparan sulfate in axon guidance during the
brain development in mice [93], HS6ST1 is suggested to be
important during the development and migration of GnRH
neurons in humans.
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3.13. SEMA3A and SEMA7A. It is well known that GnRH
neurons are generated outside the brain, in the nasal placode,
and migrate along olfactory/vomeronasal nerves reaching
the hypothalamus by the time of birth. This migration
occurs thanks to specific key players as semaphorins [94].
Their important role was reinforced with the identification
of semaphorin mutations in patients with developmental
neuroendocrine deficiencies associated with infertility [2,
94–96]. Some studies reported that a particular semaphorin,
semaphorin 3A, encoded by human SEMA3A, on chro-
mosome 7p12.1, if mutated both in humans and mice,
could lead to abnormal migration of GnRH neurons to the
hypothalamus, leading to hypogonadism and infertility [94–
96] (Figure 1). So far, twelve different SEMA3A mutations,
leading to KS phenotype, were detected in patients of both
sexes [95–97]. All these variants were identified in heterozy-
gous state, suggesting an autosomal dominant transmission,
similar to the inheritance mode reported in KS patients with
FGFR1mutations [39].
In 2011, a new candidate gene, SEMA7A, was added to
the already long list of genes related to hypogonadotropic
hypogonadism (Table 1) [98]. In this study SEMA7A was
implicated in the normal development of the GnRH1 system
in mice and was suggested to be a strong genetic marker
for some forms of GnRH1 deficiency in humans. For the
first time, in a recent study, mutations of the gene SEMA7A,
mapping on human chromosome 15q22.3-q23, were detected
in two hypogonadic patients, a male with nHH, harbouring
also a KISS1mutation, and a male with KS, harbouring also a
KAL1mutation [97]. On the basis of these results, Känsäkoski
and colleagues suggest that the identified mutations are
not sufficient, alone, to cause the pathology. Therefore, a
di/oligogenic inheritance is assumed [97].
3.14. LHB and FSHB. Gonadotropins are eterodimers com-
posed by a 𝛼-subunit, (common for TSH, FSH, LH, and
hCG) and a specific 𝛽-subunit. So far, no mutations in
the gene CGA, encoding the 𝛼-subunit, were identified,
whereas, in some male and female patients, presenting with
delayed puberty, several mutations were detected in the genes
encoding the 𝛽-subunits of LH and FSH [99, 100].
Homozygous mutations in the LHB gene, (chromosome
19q13.32), abolishing the activity of LH, have been reported to
date in sevenmen and twowomen [101–104]. In affectedmen,
sexual differentiation is normal, but the absence of LH alters
Leydig cells’ proliferation and maturation, impairing sper-
matogenesis [101]. Women, harbouring an inactivating LHB
mutation, have normal pubertal development and menarche,
followed by oligomenorrhea and secondary amenorrhea
[101]. Fewdata present in the literature, describingLHBmuta-
tions, suggest that one copy of the LH beta is sufficient for
normal LH secretion and function of the gonadotropic axis,
indeed, only the patients harbouring homozygous mutations
showed hypogonadism whereas their relatives, harbouring a
heterozygous variant, did not show clinical manifestations
[101, 102].
The FSHB gene, located on chromosome 11p13, is com-
posed of three exons but only exons 2 and 3 encode for the
mature peptide. To date, four distinct FSHB mutations were
described in four unrelated female patients with hypogo-
nadism and three mutations were described in three CHH
male patients [99, 100]. Affected women presented delayed
puberty, lack of or poor breast development, and primary
amenorrhea. After treatment with exogenous FSH, follicular
maturation, ovulation, and fertility were achieved in two
women. All affected men presented with small testes and
azoospermia, but only onemanpresented absence of pubertal
development [99, 100]. Data in the literature suggest that the
presence of undetectable serum FSH and high serum LH
levels in CHH patients of both sexes could be strongly due
to molecular defects in the FSHB gene [99, 100].
3.15. NDN. Necdin belongs to the protein superfamily
MAGE and it is able to activate GnRH expression and GnRH
neurons development in rodents [105]. Human necdin,
encoded by NDN gene (chromosome 15), has a potential
role in the onset of hypogonadism in patients affected
by Prader-Willi syndrome [106]. Few years ago, Beneduzzi
and colleagues [105] identified a rare necdin variant in
association with a mutation in FGFR1, in a patient with
familial KS. Nevertheless, functional studies showed that the
mutated necdin was able to activate the GnRH expression
as the wild type protein [105]. Further studies are needed
to clarify the role of this protein in puberty and in human
reproduction.
3.16. TSHZ1. As mentioned before, the CHH subjects may
show developmental abnormalities such as cleft palate, hear-
ing loss, and other midline defects. However, it is unclear
which CHH-associated gene is involved and to which extent
in determining these developmental defects.
In 2007, the inactivation of themurine geneTshz1 demon-
strated its role in the development of soft palate, axial skele-
ton, and middle ear in mice, suggesting the involvement of
the human geneTSHZ1 (Teashirt Zinc FingerHomeobox 1) in
subjects with palate, skeletal, and ear abnormalities [107]. Few
years later, investigating on small pool of individuals affected
by syndromic orofacial cleft (OFC), palate abnormalities, and
congenital aural atresia (CAA), mutations on TSHZ1 gene
were detected, showing an autosomal-dominant segregation
[108, 109].
More recently, Ragancokova and colleagues investigated
the role of Tshz1 in mice, showing that the inactivation
of this gene can cause olfactory bulb hypoplasia and a
severe olfactory deficit [110]. In addition, this study evaluated
olfaction of patients with TSHZ1 heterozygous mutations,
affected by CAA, and these showed hyposmia [110]. Further
gene expression analyses showed a key role of TSHZ1 in
regulating the expression of PROKR2, which is associated to
Kallmann Syndrome [110].
Considering these data, the TSHZ1 gene is suspected to
be involved, in a direct or indirect manner, and might be
included in the panel of CHH-associated genes (Table 1).
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4. Digenic and Oligogenic Inheritance
For a long period CHH were considered a monogenic
pathology with Mendelian inheritance. In 2006, researchers
began thinking about hypogonadotropic hypogonadism as a
digenic disorder. Since that time, other researchers described
cases of digenic mutations in normosmic HH or KS [14, 52].
Indeed, defects in different genes could act synergistically
to induce the CHH/KS phenotype or to modify the severity
of the GnRH deficiency [15, 52]. In 2010, Sykiotis et al. [14]
identified 10 CHH patients harbouring rare digenic protein-
altering variants and 18 CHH patients harbouring oligogenic
known or predicted deleterious mutations. In 2011, Quaynor
et al. [52] contributed to these data describing 48 normosmic
CHH patients, screened for 13 disease-related genes. In 12.5%
of these affected subjects digenic mutations were identified.
Moreover, Quaynor and colleagues [52] suggested that a
proportion of isolatedGnRHdeficiency could be attributable,
in addition to digenic/oligogenic component, to nongenetic
components, as in the cases of occasional adult onset of the
disease after normal puberty and reproductive function in
subjects without mutations.
Nevertheless, findings from the literature indicate that
monogenic mutations account for most cases of CHH (over
80%) [14, 15, 52].
5. Conclusions
In conclusion, genetic alterations in twenty-four different
genes, described so far in the literature and related to Central
Hypogonadotropic Hypogonadism, have been reported. All
these causative variants account for only 40–45% of affected
patients, suggesting the involvement of other loci and/or epi-
genetic mechanisms. From the published data, the oligogenic
nature of the disease emerges even more.
Considering the complexity of CHH, we believe that
the best genetic investigative approach could be the use
of laboratory methods, such as next generation sequencing
(NGS), allowing the simultaneous screening of many genes.
To date, little attention was given to the many non-
pathogenic single nucleotide polymorphisms (SNPs) found
in these genes. Although the polymorphic variants, described
in the literature, are not considered pathologic, they could
influence the phenotype, especially if occurring in combi-
nation with other mutations in other genes. Therefore, we
believe that their role should not be underestimated and
future studies correlating polymorphisms, causative muta-
tions (if any), and clinical characteristics of patients should
be conducted.
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[39] C. Dodé and J.-P. Hardelin, “Kallmann syndrome,” European
Journal of Human Genetics, vol. 17, no. 2, pp. 139–146, 2009.
[40] L. R. Montenegro, L. F. G. Silveira, C. Tusset et al., “Combined
use of multiplex ligation-dependent probe amplification and
automatic sequencing for identification of KAL1 defects in
patients with Kallmann syndrome,” Fertility and Sterility, vol.
100, no. 3, pp. 854–859, 2013.
[41] E. B. Trarbach, L. G. Silveira, and A. C. Latronico, “Genetic
insights into human isolated gonadotropin deficiency,” Pitu-
itary, vol. 10, no. 4, pp. 381–391, 2007.
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